Actuate Therapeutics (NASDAQ:ACTU) Given New $20.00 Price Target at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU) had its price target raised by equities researchers at HC Wainwright to $20.00 in a research note issued on Tuesday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 88.86% from the stock’s current price.

Separately, Craig Hallum started coverage on Actuate Therapeutics in a research note on Tuesday, April 22nd. They set a “buy” rating and a $21.00 target price on the stock.

Actuate Therapeutics Stock Performance

Actuate Therapeutics stock opened at $10.59 on Tuesday. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.99. The company’s 50-day moving average price is $8.93 and its 200-day moving average price is $8.42.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.06).

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds have recently made changes to their positions in ACTU. Freestone Capital Holdings LLC purchased a new stake in Actuate Therapeutics in the fourth quarter worth about $80,000. Chicago Partners Investment Group LLC purchased a new stake in Actuate Therapeutics during the first quarter worth $70,000. Envestnet Asset Management Inc. bought a new stake in Actuate Therapeutics during the 4th quarter valued at $83,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Actuate Therapeutics in the 4th quarter valued at $84,000. Finally, Sfmg LLC bought a new position in shares of Actuate Therapeutics in the 1st quarter worth $74,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.